Similarly, cancer-type-specific DDR landscapes—such as the strong STING activation signature in triple-negative breast cancers versus the more muted response in prostate and ovarian tumors—modulate responsiveness to immunotherapy and shape rational DDR–IO combinations [155]. This evidence concerns the gene STING1 and cancer.